Stifel Nicolaus Boosts Kinnate Biopharma Price Target to 2.59
About 67% of Kinnate Biopharma's investor base is looking to short. The analysis of current outlook of investing in Kinnate Biopharma suggests that many traders are alarmed regarding Kinnate Biopharma's prospects. The current market sentiment, together with Kinnate Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Kinnate Biopharma stock news signals to limit their universe of possible portfolio assets.
Kinnate |
Kinnate Biopharma had its price objective raised by equities researchers at Stifel Nicolaus from 1.50 to 2.59 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has a hold rating on the stock. Stifel Nicolaus price target would suggest a potential upside of 3.60 percent from
Read at thelincolnianonline.com
 |
Kinnate Biopharma Fundamental Analysis
We analyze Kinnate Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kinnate Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kinnate Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Kinnate Biopharma is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Kinnate Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kinnate Biopharma stock to make a market-neutral strategy. Peer analysis of Kinnate Biopharma could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics with similar companies.
Peers
Kinnate Biopharma Related Equities
| SRZN | Surrozen | 13.10 | ||||
| CCCC | C4 Therapeutics | 11.59 | ||||
| PASG | Passage Bio | 11.11 | ||||
| SLRN | ACELYRIN, INC | 3.69 | ||||
| GLUE | Monte Rosa | 3.27 | ||||
| PALI | Palisade Bio | 1.47 | ||||
| STOK | Stoke Therapeutics | 0.72 | ||||
| DSGN | Design Therapeutics | 0.57 | ||||
| KZR | Kezar Life | 0.25 | ||||
| KROS | Keros Therapeutics | 0.21 | ||||
| EWTX | Edgewise Therapeutics | 0.07 | ||||
| WINT | Windtree Therapeutics | 0 | ||||
| BOLT | Bolt Biotherapeutics | 0.61 | ||||
| KRON | Kronos Bio | 1.47 | ||||
| LRMR | Larimar Therapeutics | 1.52 | ||||
| IPSC | Century Therapeutics | 1.79 | ||||
| GBIO | Generation Bio | 2.56 | ||||
| ERAS | Erasca | 4.65 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |